James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Tesla Motors Inc: Everything You Need to Know Before Wednesday (TSLA)

Tesla Motors (TSLA) is facing an uphill battle from here. Anything less than completely compelling Wednesday afternoon could accelerate the bearish undertow.

Groupon Inc: RBC Capital Market Was Just Stating the Obvious About GRPN

Before you go bottom-fishing for GRPN stock, you may want to process a quick reality check about its plausible future.

Why Baidu Inc (ADR) (BIDU), Brocade Communications Systems, Inc. (BRCD) and Valeant Pharmaceuticals Intl Inc (VRX) Are 3 of Today’s Worst Stocks

Baidu (BIDU), Brocade (BRCD) and Valeant (VRX) were doomed from the beginning of Monday's session. Here's why.

Pfizer Inc.: Why PFE Stock Isn’t as Wild as It Seems

Pfizer (PFE) is going to unveil its first quarter numbers Tuesday morning, and more volatility is likely to be in the cards.

Why Gilead Sciences, Inc. (GILD), Stericycle Inc (SRCL) and Western Digital Corp (WDC) Are 3 of Today’s Worst Stocks

Gilead Sciences (GILD), Stericycle (SRCL) and Western Digital (WDC) were all doomed from the beginning of Friday's trading.